37.70
price up icon2.00%   0.74
after-market Handel nachbörslich: 37.79 0.09 +0.24%
loading
Schlusskurs vom Vortag:
$36.96
Offen:
$37.27
24-Stunden-Volumen:
1.16M
Relative Volume:
0.66
Marktkapitalisierung:
$4.50B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-7.1673
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-0.82%
1M Leistung:
+16.25%
6M Leistung:
-19.48%
1J Leistung:
-34.34%
1-Tages-Spanne:
Value
$36.94
$37.84
1-Wochen-Bereich:
Value
$36.71
$39.47
52-Wochen-Spanne:
Value
$29.31
$61.38

Cytokinetics Inc Stock (CYTK) Company Profile

Name
Firmenname
Cytokinetics Inc
Name
Telefon
(650) 624-3000
Name
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
498
Name
Twitter
@Cytokinetics
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CYTK's Discussions on Twitter

Vergleichen Sie CYTK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CYTK
Cytokinetics Inc
37.70 4.54B 18.47M -589.53M -399.80M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-24 Eingeleitet Barclays Overweight
2025-02-07 Eingeleitet Citigroup Buy
2025-01-22 Eingeleitet Stifel Buy
2024-11-08 Eingeleitet RBC Capital Mkts Outperform
2024-08-13 Herabstufung Goldman Buy → Neutral
2024-01-24 Herabstufung UBS Buy → Neutral
2024-01-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-11-09 Eingeleitet Goldman Buy
2023-11-07 Eingeleitet B. Riley Securities Buy
2023-08-15 Eingeleitet SVB Securities Outperform
2023-02-17 Eingeleitet BofA Securities Neutral
2022-12-23 Bestätigt Needham Buy
2022-12-20 Eingeleitet Truist Buy
2022-10-11 Eingeleitet UBS Buy
2022-01-28 Eingeleitet Goldman Buy
2021-12-22 Eingeleitet Oppenheimer Outperform
2021-12-10 Eingeleitet JP Morgan Overweight
2021-10-07 Eingeleitet Jefferies Buy
2021-03-12 Eingeleitet Wolfe Research Outperform
2021-02-18 Eingeleitet Barclays Overweight
2021-01-20 Bestätigt H.C. Wainwright Buy
2020-10-29 Eingeleitet Goldman Neutral
2020-07-10 Eingeleitet Raymond James Strong Buy
2020-05-05 Eingeleitet Mizuho Buy
2020-04-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2018-09-10 Fortgesetzt Morgan Stanley Equal-Weight
2017-11-22 Bestätigt Morgan Stanley Overweight
2017-11-22 Herabstufung Needham Strong Buy → Buy
2017-11-21 Bestätigt H.C. Wainwright Buy
2017-07-31 Eingeleitet Morgan Stanley Overweight
2017-03-08 Eingeleitet Rodman & Renshaw Buy
2017-02-06 Hochstufung Needham Buy → Strong Buy
2016-12-16 Eingeleitet Cantor Fitzgerald Overweight
2016-07-28 Bestätigt Needham Buy
2015-11-10 Bestätigt FBR Capital Outperform
2015-11-09 Bestätigt ROTH Capital Buy
2015-07-24 Bestätigt MLV & Co Buy
2014-12-31 Bestätigt ROTH Capital Buy
2014-11-04 Hochstufung MLV & Co Hold → Buy
2014-04-28 Bestätigt Needham Buy
Alle ansehen

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Cytokinetics Incorporated stock pricePowerful profit generation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Cytokinetics Incorporated stockRapid wealth creation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Cytokinetics Incorporated a good long term investmentOutstanding trading profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

Cytokinetics Incorporated Stock Analysis and ForecastMarket-beating performance - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Cytokinetics Awards 220,000 Shares in Employee Stock Grants at $38.68 Strike Price - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks

Jul 18, 2025
pulisher
Jul 15, 2025

Cytokinetics CEO Makes a Significant Stock Move! - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com Australia

Jul 15, 2025
pulisher
Jul 15, 2025

Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cytokinetics Incorporated stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Cytokinetics Incorporated stock price move sharplyDaily Swing Candidates - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire

Jul 14, 2025
pulisher
Jul 11, 2025

CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 10, 2025

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - The Manila Times

Jul 10, 2025
pulisher
Jul 10, 2025

Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 - Quiver Quantitative

Jul 10, 2025
pulisher
Jul 09, 2025

Cytokinetics(CYTK) Soars 6.93% on Analyst Optimism - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire

Jul 09, 2025
pulisher
Jul 06, 2025

Cytokinetics (CYTK): Balancing Optimism and Caution in Aficamten's High-Stakes Journey - AInvest

Jul 06, 2025
pulisher
Jul 01, 2025

CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire

Jul 01, 2025
pulisher
Jun 27, 2025

CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire

Jun 27, 2025
pulisher
Jun 25, 2025

Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress - Yahoo.co

Jun 25, 2025
pulisher
Jun 23, 2025

11 Best Most Active Stocks To Buy According to Analysts - Insider Monkey

Jun 23, 2025
pulisher
Jun 20, 2025

Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth? - Smartkarma

Jun 20, 2025
pulisher
Jun 19, 2025

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com

Jun 19, 2025
pulisher
Jun 18, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 18, 2025
pulisher
Jun 17, 2025

Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Cytokinetics CEO Robert Blum sells $169,000 in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 15, 2025

Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook By Investing.com - Investing.com India

Jun 15, 2025
pulisher
Jun 14, 2025

Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times

Jun 10, 2025
pulisher
Jun 09, 2025

JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | CYTK Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Cytokinetics (CYTK) Target Price Cut by JPMorgan Analyst | CYTK Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

JP Morgan Lowers Price Target for Cytokinetics (CYTK) to $53 | C - GuruFocus

Jun 09, 2025
pulisher
Jun 06, 2025

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - mx.advfn.com

Jun 06, 2025
pulisher
Jun 06, 2025

Shareholders That Lost Money on Cytokinetics, Incorporated(CYTK) Should Contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire

Jun 06, 2025

Finanzdaten der Cytokinetics Inc-Aktie (CYTK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):